Single Nucleotide Polymorphism (SNP) Genotyping Market Overview
As per MRFR analysis, the Single Nucleotide Polymorphism (SNP) Genotyping Market Size was estimated at 5.16 (USD Billion) in 2022. The Single Nucleotide Polymorphism (SNP) Genotyping Market Industry is expected to grow from 5.76(USD Billion) in 2023 to 15.6 (USD Billion) by 2032. The Single Nucleotide Polymorphism (SNP) Genotyping Market CAGR (growth rate) is expected to be around 11.7% during the forecast period (2024 - 2032).
Key Single Nucleotide Polymorphism (SNP) Genotyping Market Trends Highlighted
The growth of the Single Nucleotide Polymorphism (SNP) Genotyping Market can be attributed to the increase in awareness related to personalized medicine, the availability of various sequencing technologies, along the aging population as a major factor. SNP genotyping demands wild supply growth due to its usage in clinical diagnostics, drug discovery and genetic studies.
The last few years have seen changes in the market response to the increased use of platforms that support high throughput sequencers that also lower the time and cost of genotyping numerous samples. Furthermore, the utilization of polymorphism single nucleotide arrays and next-generation sequencing (NGS) leads to better genotyping resolution and accuracy.
Untapped opportunities for market growth are improvement in existing genotyping methods and the emergence of new methods, such as target enrichment for single-cell genotyping and targeting specific sequences in the genome using CRISPR. These technologies are likely to enhance the differentiation power of genotyping and broaden its applications in precision medicine and targeted therapy.
Source Primary Research, Secondary Research, MRFR Database and Analyst Review
Single Nucleotide Polymorphism (SNP) Genotyping Market Drivers
Rising Prevalence of Genetic Diseases
The increasing prevalence of genetic diseases is a major driver of the growth of the Single Nucleotide Polymorphism (SNP) Genotyping Market Industry. Variations in the DNA sequence cause genetic diseases, and SNPs are the most common type of genetic variation. As the prevalence of genetic diseases rises, there is a growing need for accurate and reliable methods to identify and diagnose these diseases. SNP genotyping is a powerful tool for identifying SNPs, and it is increasingly being used in the diagnosis and management of genetic diseases.
Technological Advancements
Technological advancements are another key driver of the growth of the Single Nucleotide Polymorphism (SNP) Genotyping Market Industry. Recent advances in DNA sequencing and genotyping technologies have made it faster, cheaper, and more accurate to identify SNPs. This has led to an increase in the use of SNP genotyping in a variety of applications, including research, diagnostics, and personalized medicine.
Growing Demand for Personalized Medicine
The expansion in the demand for personalized medicine is another essential factor fueling the increase of the Single Nucleotide Polymorphism SNP genotyping Market Industry. Personalized medicine is a concept related to health care that is based on the genetic data of a specific individual to design an appropriate treatment plan. SNP genotyping may help identify the genetic characteristics that promote the development of a specific disease.Finally, with the help of this information, it is feasible to develop an individual treatment plan, which is likely to be more effective in comparison to standard measures.
Single Nucleotide Polymorphism (SNP) Genotyping Market Segment Insights
Single Nucleotide Polymorphism (SNP) Genotyping Market Technology Insights
The Single Nucleotide Polymorphism (SNP) Genotyping Market is segmented by technology into PCR-Based Genotyping, Sequencing-Based Genotyping, and Chip-Based Genotyping. PCR-Based Genotyping is the most commonly used technology for SNP genotyping. It is a well-established and cost-effective method that can be used to genotype a large number of samples quickly and accurately.
PCR-Based Genotyping is based on the polymerase chain reaction (PCR), which is a technique that allows for the amplification of specific DNA sequences. In PCR-Based Genotyping, PCR is used to amplify the DNA region containing the SNP of interest, and then the amplified DNA is analyzed to determine the genotype of the sample.Sequencing-Based Genotyping is a more expensive and time-consuming method than PCR-Based Genotyping, but it can provide more accurate and detailed information about the genotype of a sample. Sequencing-based genotyping involves sequencing the DNA region containing the SNP of interest and then analyzing the sequence data to determine the genotype of the sample. Chip-based genotyping is a high-throughput method that can be used to genotype a large number of samples quickly and accurately. Chip-based genotyping involves using a microarray chip that contains probes for the SNP of interest.The DNA samples are hybridized to the chip, and then the chip is scanned to determine the genotype of each sample. The Single Nucleotide Polymorphism (SNP) Genotyping Market is expected to grow significantly in the coming years, driven by the increasing demand for personalized medicine and the growing adoption of genomic technologies.
Source Primary Research, Secondary Research, MRFR Database and Analyst Review
Single Nucleotide Polymorphism (SNP) Genotyping Market Application Insights
The Single Nucleotide Polymorphism (SNP) Genotyping Market is segmented by Application into Pharmacogenomics, Genetic Testing, Disease Diagnosis, and Forensic Science. In 2023, the Pharmacogenomics segment accounted for the largest revenue share of around 32.5%. The growth of this segment can be attributed to the increasing use of SNP genotyping in personalized medicine and the development of new drugs that target specific genetic variants. The Genetic Testing segment is expected to grow at a CAGR of around 12.5% during the forecast period.This growth can be attributed to the increasing demand for genetic testing for disease diagnosis and carrier screening. The Disease Diagnosis segment is expected to grow at a CAGR of around 11.8% during the forecast period. This growth can be attributed to the increasing use of SNP genotyping in the diagnosis of complex diseases such as cancer and diabetes. The Forensic Science segment is expected to grow at a CAGR of around 10.2% during the forecast period. This growth can be attributed to the increasing use of SNP genotyping in forensic investigations to identify individuals and determine their relationships.
Single Nucleotide Polymorphism (SNP) Genotyping Market Sample Type Insights
The Single Nucleotide Polymorphism (SNP) Genotyping Market is segmented by Sample Type into DNA, RNA, Blood, and Saliva. DNA is the most commonly used sample type for SNP genotyping, accounting for over 60% of the market revenue in 2023. This is because DNA is a stable molecule that can be easily extracted from a variety of sources, including blood, saliva, and tissue. RNA is also a commonly used sample type for SNP genotyping, but it is less stable than DNA and requires more careful handling. Blood is a less common sample type for SNP genotyping, but it can be used to obtain a large number of samples from a single individual.Saliva is a non-invasive sample type that can be easily collected, making it a convenient option for large-scale studies. The growth of the market is being driven by the increasing demand for personalized medicine and the development of new technologies for SNP genotyping.
Single Nucleotide Polymorphism (SNP) Genotyping Market End User Insights
The end user segment of the Single Nucleotide Polymorphism (SNP) Genotyping Market is diverse, encompassing research labs, pharmaceutical companies, clinical laboratories, and forensic labs. Research labs contribute significantly to market revenue, utilizing SNP genotyping for genetic research and drug discovery. Pharmaceutical companies leverage SNP genotyping in drug development and personalized medicine, driving market growth. Clinical laboratories offer SNP genotyping services for disease diagnosis, prognosis, and treatment selection, representing a substantial market segment.Forensic labs employ SNP genotyping in DNA fingerprinting and human identification, contributing to the overall market size. Market segmentation provides valuable insights for stakeholders, enabling them to target specific end-user segments and develop tailored strategies to capture market opportunities.
Single Nucleotide Polymorphism (SNP) Genotyping Market Regional Insights
The Single Nucleotide Polymorphism (SNP) Genotyping Market is segmented into North America, Europe, APAC, South America, and MEA. North America held the largest market share in 2023, owing to the presence of major market players, advanced healthcare infrastructure, and high adoption of genetic testing. Europe is expected to be the second-largest market due to the increasing prevalence of chronic diseases and growing awareness about personalized medicine. APAC is expected to witness the fastest growth during the forecast period, owing to the rising disposable income, increasing healthcare expenditure, and growing awareness about genetic testing in emerging economies such as China and India.South America and MEA are expected to have a relatively smaller market share but are expected to grow at a steady pace during the forecast period.
Source Primary Research, Secondary Research, MRFR Database and Analyst Review
Single Nucleotide Polymorphism (SNP) Genotyping Market Key Players And Competitive Insights
Major Single Nucleotide Polymorphism (SNP) Genotyping Market players are constantly trying to increase their market share by investing in research and development expanding their product range, and by buying out smaller companies. The heavy competition in the Single Nucleotide Polymorphism (SNP) Genotyping Market is forcing companies to innovate, and as a result, the upper limit of the market potential is constantly being pushed. The technological innovations that prominent players in the Single Nucleotide Polymorphism (SNP) Genotyping Market are focusing on consist of implementing novel techniques, such as next-generation sequencing, to speed up the process and make it more accurate. Many companies in the SNP industry are also producing companion diagnostics, which allows doctors to provide more personalized treatment to patients. Mergers and acquisitions of smaller companies by the major players for market expansion and de-correlation with other companies will continue in the future.
Illumina is one of the most prominent players in the Single Nucleotide Polymorphism (SNP) Genotyping Market, and the company has been active in the field of SNP for a long time. Based on its collection of technologies, products, and services, well-established experience, and strong track record of innovation, Illumina is in an excellent position to compete in the Single Nucleotide Polymorphism (SNP) Genotyping Market. The company's best-selling product, NextSeq, is one of the most widely used sequencing instruments in the world. In addition to SNP genotyping, the product is used in cell and gene genome sequencing. Another Illumina product that is widely used for SNP genotyping is MiSeq technology. Illumina also provides a range of reagents and software for SNP analysis, so the end-to-end solution provided by the company is commendable. Illumina's brand is associated with high-quality service and technology, and the company has a large customer base.
Another major Single Nucleotide Polymorphism (SNP) Genotyping Market player is Thermo Fisher Scientific. The company owns the Ion Torrent sequencing technology, which is known for its speed and low price. Ion Torrent is widely used for high-throughput SNP genotyping. The consumables and reagents for SNP analysis produced by the company complement the sequencing tools. Thermo Fisher Scientific is considered to be a serious competitor in the Single Nucleotide Polymorphism (SNP) Genotyping Market due to its strong presence in the life sciences industry and its significant investment in research and development.
Key Companies in the Single Nucleotide Polymorphism (SNP) Genotyping Market Include
Single Nucleotide Polymorphism (SNP) Genotyping Market Industry Developments
The Single Nucleotide Polymorphism (SNP) Genotyping Market is anticipated to reach a value of USD 5.76 billion by 2023, exhibiting a CAGR of 11.7% from 2024 to 2032. Technological advancements, the rising prevalence of chronic diseases, and the increasing adoption of personalized medicine are key drivers of market growth. Recent developments include collaborations between companies such as Thermo Fisher Scientific and Illumina to enhance genotyping accuracy and throughput. Additionally, the integration of artificial intelligence (AI) and machine learning (ML) in SNP genotyping workflows is streamlining data analysis and improving result interpretation. Furthermore, the growing adoption of next-generation sequencing (NGS) platforms is expected to fuel market expansion, enabling researchers and clinicians to analyze large-scale genetic variations and identify disease-associated SNPs.
Single Nucleotide Polymorphism (SNP) Genotyping Market Segmentation Insights
Single Nucleotide Polymorphism (SNP) Genotyping Market Technology Outlook
- PCR-Based Genotyping
- Sequencing-Based Genotyping
- Chip-Based Genotyping
Single Nucleotide Polymorphism (SNP) Genotyping Market Application Outlook
- Pharmacogenomics
- Genetic Testing
- Disease Diagnosis
- Forensic Science
Single Nucleotide Polymorphism (SNP) Genotyping Market Sample Type Outlook
Single Nucleotide Polymorphism (SNP) Genotyping Market End User Outlook
- Research Labs
- Pharmaceutical Companies
- Clinical Laboratories
- Forensic Labs
Single Nucleotide Polymorphism (SNP) Genotyping Market Regional Outlook
- North America
- Europe
- South America
- Asia-Pacific
- Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2022 |
5.16(USD Billion) |
| Market Size 2023 |
5.76(USD Billion) |
| Market Size 2032 |
15.6(USD Billion) |
| Compound Annual Growth Rate (CAGR) |
11.7% (2024 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2022 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
Veracyte, 10X Genomics, Invivoscribe, Thermo Fisher Scientific, Illumina, QIAGEN, Myriad Genetics, Nanostring Technologies, Oxford Nanopore Technologies, BioRad Laboratories, Roche, Pacific Biosciences of California, Agilent Technologies, Personalis, Invitae |
| Segments Covered |
Technology, Application, Sample Type, End User, Regional |
| Key Market Opportunities |
Growth in pharmacogenomics increasing demand for personalized medicine technological advancements, untapped potential in emerging markets, expanding applications in agriculture |
| Key Market Dynamics |
Increasing demand for personalized medicine Advancements in sequencing technologies Growing prevalence of genetic diseases Rising government support for genomic research Technological improvements in SNP genotyping assays |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The SNP Genotyping Market is projected to reach a valuation of 15.6 billion USD by 2032.
The SNP Genotyping Market is expected to register a CAGR of 11.7% from 2024 to 2032.
North America is expected to hold the largest market share in the SNP Genotyping Market, followed by Europe and Asia-Pacific.
Key applications of SNP Genotyping include genetic testing, disease diagnosis, personalized medicine, and drug development.
Major competitors in the SNP Genotyping Market include Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, and Bio-Rad Laboratories.
Growth drivers of the SNP Genotyping Market include increasing demand for genetic testing, advancements in sequencing technologies, and growing adoption of personalized medicine.
Challenges faced by the SNP Genotyping Market include high costs of genotyping, data interpretation complexities, and ethical concerns related to genetic information.
Emerging trends in the SNP Genotyping Market include the development of next-generation sequencing technologies, the integration of artificial intelligence, and the increasing use of SNP genotyping in non-invasive prenatal testing.
Potential opportunities for the SNP Genotyping Market include the growing demand for precision medicine, the expansion of genetic testing into new applications, and the development of novel SNP genotyping technologies.
